- Home
- NUVL vs UPST Comparison
NUVL vs UPST Comparison
Compare NUVL & UPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- UPST
- Stock Information
- Founded
- NUVL 2017
- UPST 2012
- Country
- NUVL United States
- UPST United States
- Employees
- NUVL N/A
- UPST N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- UPST Finance: Consumer Services
- Sector
- NUVL Health Care
- UPST Finance
- Exchange
- NUVL Nasdaq
- UPST Nasdaq
- Market Cap
- NUVL 6.7B
- UPST 6.8B
- IPO Year
- NUVL 2021
- UPST 2020
- Fundamental
- Price
- NUVL $75.84
- UPST $62.96
- Analyst Decision
- NUVL Strong Buy
- UPST Buy
- Analyst Count
- NUVL 11
- UPST 11
- Target Price
- NUVL $112.36
- UPST $65.44
- AVG Volume (30 Days)
- NUVL 558.9K
- UPST 4.8M
- Earning Date
- NUVL 02-25-2025
- UPST 02-11-2025
- Dividend Yield
- NUVL N/A
- UPST N/A
- EPS Growth
- NUVL N/A
- UPST N/A
- EPS
- NUVL N/A
- UPST N/A
- Revenue
- NUVL N/A
- UPST $604,944,000.00
- Revenue This Year
- NUVL N/A
- UPST $11.45
- Revenue Next Year
- NUVL N/A
- UPST $35.13
- P/E Ratio
- NUVL N/A
- UPST N/A
- Revenue Growth
- NUVL N/A
- UPST 10.89
- 52 Week Low
- NUVL $61.80
- UPST $20.60
- 52 Week High
- NUVL $113.51
- UPST $88.95
- Technical
- Relative Strength Index (RSI)
- NUVL 38.09
- UPST 46.66
- Support Level
- NUVL $69.58
- UPST $55.20
- Resistance Level
- NUVL $78.18
- UPST $65.77
- Average True Range (ATR)
- NUVL 3.03
- UPST 3.32
- MACD
- NUVL 0.04
- UPST -0.04
- Stochastic Oscillator
- NUVL 50.40
- UPST 47.26
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About UPST Upstart Holdings Inc. Common stock
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.